ReviewDer Pathologe2015
[Novel biomarkers in renal cell carcinoma. Identification and functional characterization].
Review in Der Pathologe, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to advanced imaging techniques, renal cell carcinoma (RCC) is now identified earlier, often in localized stages. As a result, nephron-sparing surgical resection is possible in most cases. The development of new targeted therapies has changed the way metastatic RCC is treated. Despite this positive trend with improved survival rates and expanding treatment options, reliable biomarkers for better predicting disease course are lacking. These are urgently needed to enable personalized therapy based on the treatment-associated risks, the presence of comorbidities, and molecular tumor characteristics. We were able to show that proteins with a regulatory influence on apoptotic signal cascades represent not only promising prognostic markers, but also interesting targets for new therapeutic approaches. Furthermore, our data demonstrate that molecular tests are necessary to correctly classify a RCC with Xp11.2 translocation, since in addition to translocation, amplification can also result in TFE3 activation. Translational research with RCC biomarker identification and establishment, as well as molecular characterization and subtyping of RCCs is required to guide therapeutic decisions and enable personalized medicine in RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.